RRx-001, a First-in-class Small Molecule Inhibitor of MYC and a Downregulator of CD47, is an "Erythrophagoimmunotherapeutic"
ONCOIMMUNOLOGY(2020)
摘要
The main mechanism of action of RRx-001, a pharmaceutically unprecedented sui generis Phase 3 small molecule that is derived from the aerospace industry, is clarified. RRx-001 has demonstrated anticancer activity through antiangiogenic, immune, epigenetic, antioxidant, apoptotic and nitric oxide (NO) pathways, resulting in its pleiomorphic description as an antiangiogenic/vascular normalizer.
更多查看译文
关键词
immunotherapy,small molecule,erythrophagoimmunotherapeutic,myc,cd47,hemoglobin,tumor associated macrophage
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要